Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087877 | 0.92 | LMNA (0.51) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL994265 | 0.83 | ALDH1A1 (0.38) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL16501126 | 0.82 | ALDH1A1 (0.35) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL9451016 | 0.81 | MEN1 (0.44) | SMN1; SMN2TSHRCCNB2CDK1CCNB1 | |
| SCHEMBL14062434 | 0.80 | SLC6A2 (0.38) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL11544779 | 0.79 | MAPT (0.48) | LMNAALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL13651803 | 0.77 | SLC6A2 (0.53) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL11937216 | 0.76 | LMNA (0.49) | LMNAALDH1A1SMN1; SMN2ACHEKIF11 | |
| SCHEMBL14062463 | 0.76 | KIF11 (0.39) | LMNAALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL1262399 | 0.76 | SLC6A2 (0.51) | LMNAALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| US-8088346-B2 | Alkene hydrofunctionalization reactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20090069580-A1 | Alkene Hydrofunctionalization Reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | LMNA 1238/4885ALDH1A1 721/4885SMN1; SMN2 1743/4885 |
| US-20090069580-A1 | Alkene Hydrofunctionalization Reactions | ADH1A, ADH1C, ADH5 | LMNA 4446/4885ALDH1A1 28/4885SMN1; SMN2 3156/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | LMNA 1077/4885ALDH1A1 537/4885SMN1; SMN2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.